Organization | University of Burgundy

University of Burgundy Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Dijon France (1722)

Organization Overview

First Clinical Trial

2006

NCT00658463

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Centre G. F. Leclerc-DIJON | Centre Hospitalier Universitaire de Dijon | Centre Hospitalier Universitaire Dijon | CH DIJON | CHU de BOCAGE, DIJON, FRANCE | CHU Dijon | CHU DIJON | CHU SITE DU BOCAGE - DIJON CEDEX | Dijon University | Dijon University Hospital | University of Burgundy

Active Ingredients

Drugs in Phase 4 Trials (22)

citrasate (2 trials)

dapagliflozin (farxiga) (1 trial)

dexamethasone (2 trials)

escitalopram (lexapro) (1 trial)

fluocinolone acetonide (synalar) (1 trial)

heparin (liquaemin) (2 trials)

insulin detemir (Levemir) (1 trial)

insulin glulisine (Apidra) (1 trial)

insulin human (humulin) (3 trials)

levobupivacaine (chirocaine) (2 trials)

liraglutide (victoza) (4 trials)

omalizumab (xolair) (1 trial)

pioglitazone (actos) (1 trial)

propofol (diprivan) (3 trials)

ropivacaine (naropin) (4 trials)

rosuvastatin (crestor) (1 trial)

sertraline (zoloft) (1 trial)

sevoflurane (ultane) (3 trials)

sitagliptin (januvia) (1 trial)

sodium chloride (5 trials)

tramadol (Ultram) (1 trial)

vildagliptin (1 trial)

Drugs in Phase 3 Trials (34)

2-fluoropyrimidine (1 trial)

abobotulinumtoxinA (Dysport) (1 trial)

aflibercept (zaltrap) (1 trial)

bevacizumab (avastin) (3 trials)

bleomycin (blenoxane) (1 trial)

bortezomib (velcade) (1 trial)

cyclophosphamide (cytoxan) (2 trials)

dexmedetomidine (precedex) (1 trial)

doxorubicin (Doxil) (2 trials)

etoposide (vepesid) (1 trial)

fluorouracil (efudex) (4 trials)

glucose (1 trial)

interferon alpha-2b (Intron-A) (2 trials)

leucovorin (5 trials)

levosimendan (1 trial)

melphalan (alkeran) (2 trials)

methotrexate (2 trials)

methylprednisolone (medrol) (2 trials)

multivitamins (1 trial)

mycophenolate (myfortic) (1 trial)

nivolumab (opdivo) (1 trial)

norepinephrine (levophed) (1 trial)

oxaliplatin (eloxatin) (4 trials)

pravastatin (pravachol) (2 trials)

prednisone (meticorten) (6 trials)

procarbazine (matulane) (1 trial)

rifaximin (xifaxan) (1 trial)

rituximab (rituxan) (2 trials)

semaglutide (Ozempic) (1 trial)

sorafenib (nexavar) (2 trials)

tenofovir (viread) (1 trial)

tocilizumab (actemra) (2 trials)

vasopressin (vasostrict) (1 trial)

vincristine (oncovin) (2 trials)

Drugs in Phase 2 Trials (15)

asparaginase (elspar) (1 trial)

carfilzomib (kyprolis) (1 trial)

ceftobiprole (1 trial)

cetuximab (erbitux) (1 trial)

clonidine (catapres) (1 trial)

daclatasvir (daklinza) (1 trial)

daptomycin (cubicin) (1 trial)

idarubicin (idamycin) (3 trials)

irinotecan (Camptosar) (3 trials)

lanreotide (somatuline depot) (1 trial)

ribavirin (virazole) (1 trial)

sirolimus (rapamune) (1 trial)

sunvepra (1 trial)

taselisib (1 trial)

ustekinumab (stelara) (2 trials)

Drugs in Phase 1 Trials (2)

ceftaroline fosamil (teflaro) (1 trial)

om-174 (1 trial)

Drugs in Other Trials (13)

acetaminophen (tylenol) (1 trial)

apolipoprotein c1 (2 trials)

apple polyphenols (1 trial)

cortisone acetate (cortone) (1 trial)

fentanyl (Innovar) (1 trial)

icosapent ethyl (vascepa) (1 trial)

nicotine (nicorette) (1 trial)

ondansetron (zofran) (1 trial)

sage extract (1 trial)

sufentanil (1 trial)

water (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acute Kidney Injury (Phase 4)

Acute Lung Injury (Phase 3)

Adenocarcinoma (Phase 3)

Aneurysm (Phase 4)

Aortic Aneurysm (Phase 4)

Aortic Aneurysm, Abdominal (Phase 4)

Arteritis (Phase 3)

Ascites (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Merkel Cell (Phase 2)

Coinfection (Phase 2)

Colonic Neoplasms (Phase 3)

Colorectal Neoplasms (Phase 3)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Fatty Liver (Phase 4)

Fibrosis (Phase 1)

Giant Cell Arteritis (Phase 3)

Heart Failure (Phase 3)

Hepatitis (Phase 3)

Hepatitis B (Phase 3)

HIV Infections (Phase 2)

Hodgkin Disease (Phase 3)

Liver Cirrhosis (Phase 1)

Liver Neoplasms (Phase 3)

Lung Diseases (Phase 3)

Lung Diseases, Interstitial (Phase 3)

Lymphoma (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Meningitis (Phase 2)

Meningitis, Pneumococcal (Phase 2)

Multiple Myeloma (Phase 3)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 3)

Overweight (Phase 4)

Peritonitis (Phase 3)

Polymyalgia Rheumatica (Phase 3)

Renal Insufficiency (Phase 4)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn (Phase 3)

Shock (Phase 3)

Shock, Septic (Phase 3)

Syndrome (Phase 3)

Telangiectasis (Phase 3)

Urticaria (Phase 4)

Uveitis (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 72
# of Trial APIs: 86